Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection

Fineline Cube Nov 3, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA

Fineline Cube Nov 3, 2023

China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...

Company

Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances

Fineline Cube Nov 3, 2023

Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...

Company

Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales

Fineline Cube Nov 3, 2023

US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...

Company Drug

Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program

Fineline Cube Nov 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...

Company Deals

AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies

Fineline Cube Nov 2, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...

Company

Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023

Fineline Cube Nov 2, 2023

Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...

Company Drug

EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting

Fineline Cube Nov 2, 2023

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...

Company

GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%

Fineline Cube Nov 2, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development

Fineline Cube Nov 2, 2023

Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...

Company Drug

Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...

Company

Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials

Fineline Cube Nov 2, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial

Fineline Cube Nov 2, 2023

China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...

Company Drug

Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial

Fineline Cube Nov 2, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...

Company Drug

Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study

Fineline Cube Nov 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...

Company Deals

3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab

Fineline Cube Nov 2, 2023

China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...

Company Deals

Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma

Fineline Cube Nov 2, 2023

US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...

Company Drug

Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery

Fineline Cube Nov 1, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...

Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection

Fineline Cube Nov 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...

Posts pagination

1 … 498 499 500 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.